Torisel: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
Ochuko Ajari (talk | contribs) No edit summary |
||
| Line 31: | Line 31: | ||
The drug is promising for RCC patients. A phase III clinical study of the drug showed a 49 percent increase in patients' median overall survival time (10.9 months).<ref>[http://www.drugs.com/nda/torisel_061006.html Drugs.com]</ref> The drug was administered to patients who had received no prior systemic therapy; however, this study only included patients with a poor prognosis. The benefits of temsirolimus in patients with favorable or intermediate prognostic factors remains to be elucidated. | The drug is promising for RCC patients. A phase III clinical study of the drug showed a 49 percent increase in patients' median overall survival time (10.9 months).<ref>[http://www.drugs.com/nda/torisel_061006.html Drugs.com]</ref> The drug was administered to patients who had received no prior systemic therapy; however, this study only included patients with a poor prognosis. The benefits of temsirolimus in patients with favorable or intermediate prognostic factors remains to be elucidated. | ||
==References== | |||
{{Reflist|2}} | |||
[[Category:Macrolide antibiotics]] | [[Category:Macrolide antibiotics]] | ||
Revision as of 14:55, 25 September 2013
| File:Temsirolimus.png | |
| Identifiers | |
|---|---|
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
|
WikiDoc Resources for Torisel |
|
Articles |
|---|
|
Most recent articles on Torisel |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Torisel at Clinical Trials.gov Clinical Trials on Torisel at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Torisel
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating Torisel Risk calculators and risk factors for Torisel
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Torisel |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007.[1] It is a derivative of the macrolide sirolimus.
The drug is promising for RCC patients. A phase III clinical study of the drug showed a 49 percent increase in patients' median overall survival time (10.9 months).[2] The drug was administered to patients who had received no prior systemic therapy; however, this study only included patients with a poor prognosis. The benefits of temsirolimus in patients with favorable or intermediate prognostic factors remains to be elucidated.
References
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Macrolide antibiotics